Sign in to view content

Three-Year Outcomes of the PALADIN Phase IV Study: Comparison of Anatomical Metrics, Efficacy, and Treatment Burden Post FAc

Christopher D. Riemann, MD

Video
Published 2022

Related

12-Month Ocular Pharmacokinetic Study of EYP-1901 a Sustained-Release Intravitreal Formulation of the Tyrosine Kinase Inhibitor Vorolanib
Rishi P. Singh, MD
Annual Meeting Talks
2023
ZETA-1 Phase 2 Trial Efficacy Results for APX3330 a Novel Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy
David R Lally, MD
Annual Meeting Talks
2023
Senolytic Candidate UBX1325 for Diabetic Macular Edema: The BEHOLD Phase 2 and ASPIRE Phase 2b Trials
Dante Joseph Pieramici, MD
Annual Meeting Talks
2025

Category: Diabetic Retinopathy

See more